Roanna Ruiz
Stock Analyst at Leerink Partners
(0.87)
# 3,970
Out of 5,162 analysts
60
Total ratings
35%
Success rate
-14.98%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $83 → $84 | $59.34 | +41.56% | 2 | Feb 26, 2026 | |
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $2.40 | -16.67% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $5.48 | +64.23% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.43 | +389.51% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $6.26 | +187.77% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.68 | -40.48% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $9.19 | +117.63% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $8.31 | +224.91% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.05 | +220.99% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.86 | +138.91% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $330 | $538.58 | -38.73% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $31.89 | -21.61% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.21 | +270.93% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $6.07 | -1.15% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $29.28 | -35.11% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $79.37 | +51.19% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $7.74 | +545.99% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.82 | +152.84% | 6 | Oct 19, 2022 |
Cytokinetics
Feb 26, 2026
Maintains: Outperform
Price Target: $83 → $84
Current: $59.34
Upside: +41.56%
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $2.40
Upside: -16.67%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $5.48
Upside: +64.23%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.43
Upside: +389.51%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $6.26
Upside: +187.77%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.68
Upside: -40.48%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $9.19
Upside: +117.63%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $8.31
Upside: +224.91%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.05
Upside: +220.99%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.86
Upside: +138.91%
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $538.58
Upside: -38.73%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $31.89
Upside: -21.61%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.21
Upside: +270.93%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $6.07
Upside: -1.15%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $29.28
Upside: -35.11%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $79.37
Upside: +51.19%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $7.74
Upside: +545.99%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.82
Upside: +152.84%